200 related articles for article (PubMed ID: 12094839)
21. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
Hanauer SB
Gut; 1999 Apr; 44(4):455. PubMed ID: 10075949
[No Abstract] [Full Text] [Related]
22. Mesalamine for ulcerative colitis.
Med Lett Drugs Ther; 1988 May; 30(766):53-4. PubMed ID: 3283508
[No Abstract] [Full Text] [Related]
23. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Muijsers RB; Goa KL
Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
[TBL] [Abstract][Full Text] [Related]
24. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
Baker DE
Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
[TBL] [Abstract][Full Text] [Related]
25. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Loftus EV; Kane SV; Bjorkman D
Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
[TBL] [Abstract][Full Text] [Related]
26. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
[TBL] [Abstract][Full Text] [Related]
27. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
[TBL] [Abstract][Full Text] [Related]
28. [Ulcerative colitis. Acute episode].
Reissmann A; Bischoff SC; Fleig W
Z Gastroenterol; 2004 Sep; 42(9):994-8. PubMed ID: 15455271
[No Abstract] [Full Text] [Related]
29. Balsalazide disodium for the treatment of ulcerative colitis.
Patil SA; Moss AC
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):177-84. PubMed ID: 19072352
[TBL] [Abstract][Full Text] [Related]
30. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
31. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
Green JR; Swan CH; Rowlinson A; Gibson JA; Brown P; Kerr GD; Swarbrick ET; Thornton P
Aliment Pharmacol Ther; 1992 Oct; 6(5):647-52. PubMed ID: 1420754
[TBL] [Abstract][Full Text] [Related]
32. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Tursi A
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
[TBL] [Abstract][Full Text] [Related]
33. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
[TBL] [Abstract][Full Text] [Related]
34. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.
Mackowiak JI
Manag Care Interface; 2006 Oct; 19(10):39-46, 56. PubMed ID: 17117598
[TBL] [Abstract][Full Text] [Related]
35. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
Giaffer MH; Holdsworth CD; Lennard-Jones JE; Rodrigues CA; McIntyre PB; Manjunatha S; Baron JH; Barrison IG; Polson RJ; Hoare AM
Aliment Pharmacol Ther; 1992 Aug; 6(4):479-85. PubMed ID: 1358234
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
[TBL] [Abstract][Full Text] [Related]
37. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
Edmond LM; Hopkins MJ; Magee EA; Cummings JH
Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
[TBL] [Abstract][Full Text] [Related]
38. [New developments in therapy with 5-aminosalicylic acid preparations in ulcerative colitis and Crohn disease].
Kruis W
Z Gastroenterol Verh; 1991 Mar; 26():154-6. PubMed ID: 1714132
[No Abstract] [Full Text] [Related]
39. 5-Aminosalicylic acid for the treatment of inflammatory bowel disease.
Dew MJ; Evans BK; Rhodes J
Gastroenterology; 1984 Aug; 87(2):480-1. PubMed ID: 6735091
[No Abstract] [Full Text] [Related]
40. Oral asacol in the treatment of mild to moderate ulcerative colitis: the Nashville experience.
Pruitt RE; Gremillion DE; Herring RW; Bailey AH; Faust TW; Potter M; Long KM
J Tenn Med Assoc; 1991 May; 84(5):237. PubMed ID: 2067380
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
